The Covid-19 pandemic might yet delay US approval of Novartis's cholesterol-lowering project Leqvio − and then come the commercial questions.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,